SCHEMBL5213619

SCHEMBL5213619

N=C1NC(=O)C(Cc2ccc(O)cc2)S1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.71
MAPT P10636 2/20 0.54
PPARG P37231 5/20 0.48
FFAR1 O14842 3/20 0.47
PPARA Q07869 2/20 0.47
ALDH1A1 P00352 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KMT2A Q03164 2/20 0.46
CA2 P00918 1/20 0.46
MEN1 O00255 1/20 0.46
RAB9A P51151 1/20 0.46
MAOA P21397 2/20 0.44
CISD1 Q9NZ45 2/20 0.44
CAPN1 P07384 1/20 0.42
LMNA P02545 1/20 0.42
GLA P06280 1/20 0.42
HPGD P15428 1/20 0.42
ALOX12 P18054 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9570622 0.92 MAOB (0.83) MAOBMAPTPPARGFFAR1PPARA
Glitazone SCHEMBL623021 0.85 MAPT (0.73) MAOBMAPTPPARGFFAR1PPARA
SCHEMBL1520158 0.84 MAOB (0.71) MAOBMAPTPPARGFFAR1PPARA
SCHEMBL1520824 0.83 MAOB (1.00) MAOBMAPTPPARGFFAR1ALDH1A1
SCHEMBL9570681 0.83 MAOB (0.69) MAOBMAPTPPARGFFAR1PPARA
SCHEMBL9515259 0.82 MAOB (0.64) MAOBMAPTPPARGFFAR1PPARA
SCHEMBL8172791 0.81 CA2 (0.71) MAOBMAPTPPARGFFAR1PPARA
SCHEMBL4221515 0.78 MAOB (0.62) MAOBMAPTPPARGFFAR1PPARA
SCHEMBL9570559 0.77 MAPT (0.83) MAOBMAPTPPARGFFAR1PPARA
SCHEMBL12521889 0.77 MAOB (0.74) MAOBPPARGFFAR1PPARACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1387843-B1 METHOD FOR OBTAINING PIOGLITAZONE AS AN ANTIDIABETIC AGENT ZENTIVA AS (CZ) 2007-02-28 EP disclosed
EP-1387843-B1 METHOD FOR OBTAINING PIOGLITAZONE AS AN ANTIDIABETIC AGENT ZENTIVA AS (CZ) 2007-02-28 EP disclosed
US-7009057-B2 Method for obtaining pioglitazone as an antidiabetic agent ZENTIVA A.S. (CZ) 2006-03-07 US disclosed
US-20050043360-A1 Method for obtaining pioglitazone as an antidiabetic agent LECIVA, A.S. (CZ) 2005-02-24 US disclosed
EP-1387843-A1 METHOD FOR OBTAINING PIOGLITAZONE AS AN ANTIDIABETIC AGENT Leciva, A.S. (CZ) 2004-02-11 EP disclosed
WO-2002088120-A1 METHOD FOR OBTAINING PIOGLITAZONE AS AN ANTIDIABETIC AGENT Léciva, a.s. (CZ) 2002-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043360-A1 Method for obtaining pioglitazone as an antidiabetic agent GLP1R, INSR, CBR3 MAOB 2836/4885MAPT 4834/4885PPARG 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.